Evidence map›Paper›PMID 42845194›Full record

ReviewJournal of microbiology and biotechnology2026

Predatory Mechanisms of Myxobacteria and Their Potential in the Development of Biocontrol Agents.

Bongsoo Lee

Abstract readReview
In one paragraph

Review in Journal of microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Bongsoo LeeDepartment of Microbial Biotechnology, Mokwon University, 88 Doanbuk-ro, Seo-gu, Daejeon 35349, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Climate change, environmental degradation, and the depletion of finite resources are intensifying the search for sustainable, bio-based solutions across agriculture, environmental management, and chemical production. Against this backdrop, myxobacteria have emerged as a valuable but still underused microbial resource, distinguished by their ecological versatility, multicellular behavior, predatory lifestyle, and biosynthetic capacity. This review integrates the mechanistic basis of myxobacterial predation with its translational potential in biocontrol, linking microbial ecology to applied biotechnology. The available evidence indicates that predation is not a single process but a coordinated program built from swarm behavior, gliding motility, contact-dependent killing, secreted hydrolytic enzymes, outer membrane vesicle (OMV)-mediated interference, nutrient competition, and specialized metabolites. Through these layers, myxobacteria antagonize phylogenetically diverse targets, including bacteria, fungi, oomycetes, and ciliates, with more limited evidence extending to cyanobacteria and nematodes. Unlike recent reviews that address either the cellular and genetic mechanisms of predation or antagonism against plant pathogens in isolation, this review connects mechanism with application and compares the maturity of the available evidence across target classes. Within this framework, selected bacterial and fungal plant-disease systems have field-level support; oomycetes are mechanistically well supported but have limited field validation; ciliates provide direct mechanistic predation evidence without biocontrol validation; cyanobacteria remain emerging with laboratory-based evidence; and nematodes remain preliminary, with evidence restricted to

Indexed as

AntibiosisBiological Control AgentsMyxococcalesPest Control, BiologicalAnimalsPlant DiseasesBiological Control AgentsBiocontrolMyxobacteriaPredationSecondary metabolites

Identifiers

PMID42845194
PMCPMC13669512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.